UY31826A - Compuesto peptídico y su uso - Google Patents
Compuesto peptídico y su usoInfo
- Publication number
- UY31826A UY31826A UY0001031826A UY31826A UY31826A UY 31826 A UY31826 A UY 31826A UY 0001031826 A UY0001031826 A UY 0001031826A UY 31826 A UY31826 A UY 31826A UY 31826 A UY31826 A UY 31826A
- Authority
- UY
- Uruguay
- Prior art keywords
- cbp501
- mammal
- peptide compound
- pharmaceutically acceptable
- drugs
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- DEZJGRPRBZSAKI-KMGSDFBDSA-N 565434-85-7 Chemical compound C([C@@H](N)C(=O)N[C@H](CO)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CO)C(=O)N[C@H](CC=1C(=C(F)C(F)=C(F)C=1F)F)C(=O)N[C@H](CC1CCCCC1)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H](CCCNC(N)=N)C(=O)N[C@H](CCCNC(N)=N)C(O)=O)C(C=C1)=CC=C1C(=O)C1=CC=CC=C1 DEZJGRPRBZSAKI-KMGSDFBDSA-N 0.000 abstract 2
- 108010089388 Cdc25C phosphatase (211-221) Proteins 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 238000011282 treatment Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención provee un método para la profilaxis o el tratamiento del cáncer en un mamífero, que comprende administrar una cantidad terapéuticamente efectiva de CBP501, una de sus pro drogas o una de sus sales farmacéuticamente aceptables al mamífero, en donde CBP501, una de sus drogas o una de sus sales farmacéuticamente aceptables es administrada simultáneamente con, o antes de, la administración de un agente que daña el ácido nucléico.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US5319008P | 2008-05-14 | 2008-05-14 | |
| US11684908P | 2008-11-21 | 2008-11-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UY31826A true UY31826A (es) | 2010-01-05 |
Family
ID=40886711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UY0001031826A UY31826A (es) | 2008-05-14 | 2009-05-13 | Compuesto peptídico y su uso |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20100112089A1 (es) |
| CN (1) | CN102149725A (es) |
| AR (1) | AR071774A1 (es) |
| CL (1) | CL2009001156A1 (es) |
| PE (1) | PE20091924A1 (es) |
| RU (1) | RU2010150964A (es) |
| TW (1) | TW201000116A (es) |
| UY (1) | UY31826A (es) |
| WO (1) | WO2009139497A1 (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110133298A (zh) * | 2012-03-18 | 2019-08-16 | 株式会社资生堂 | 疾病样品分析装置、分析系统及分析方法 |
| RU2732440C2 (ru) | 2013-06-24 | 2020-09-16 | Кэнбас Ко., Лтд. | Пептиды и пептидомиметики для комбинированного применения и лечения в субпопуляциях пациентов с раковыми заболеваниями |
| GB201401877D0 (en) | 2014-02-04 | 2014-03-19 | Univ Tromsoe | Peptides |
| US10149887B2 (en) | 2015-10-23 | 2018-12-11 | Canbas Co., Ltd. | Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment |
| TWI805542B (zh) * | 2015-10-23 | 2023-06-21 | 日商坎巴斯有限公司 | 用於癌症治療之肽及擬肽與ｔ細胞活化劑及／或查核點抑制劑之組合 |
| CN119185322A (zh) | 2015-11-20 | 2024-12-27 | 生华生物科技股份有限公司 | 用于治疗癌症的四环喹诺酮类似物组合疗法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2385257A1 (en) * | 1999-09-22 | 2001-03-29 | Canbas Co., Ltd. | Compositions and methods for inhibiting g2 cell cycle arrest and sensitizing cells to dna damaging agents |
| JP4041066B2 (ja) * | 2002-01-17 | 2008-01-30 | 武田薬品工業株式会社 | 抗増殖活性を有し、そして／または核酸損傷剤を増大するペプチドおよびペプチド模倣物あるいは処置 |
| US7125842B2 (en) * | 2003-04-07 | 2006-10-24 | Canbas Co. Ltd. | Anti-fungal compounds and methods of use |
| JP2007501608A (ja) * | 2003-08-08 | 2007-02-01 | 株式会社 キャンバス | 抗癌治療の効力を推定するための感受性試験 |
| AU2006201635A1 (en) * | 2005-10-20 | 2007-05-10 | Ludwig Institute For Cancer Research | Novel inhibitors and methods for their preparation |
| CA2666184A1 (en) * | 2006-10-11 | 2008-04-17 | Medvet Science Pty. Ltd. | The use of a dna damaging agent and a ligand for the treatment of cancer |
-
2009
- 2009-05-13 TW TW098115779A patent/TW201000116A/zh unknown
- 2009-05-13 RU RU2010150964/04A patent/RU2010150964A/ru not_active Application Discontinuation
- 2009-05-13 UY UY0001031826A patent/UY31826A/es not_active Application Discontinuation
- 2009-05-13 US US12/465,536 patent/US20100112089A1/en not_active Abandoned
- 2009-05-13 CN CN2009801279086A patent/CN102149725A/zh active Pending
- 2009-05-13 WO PCT/JP2009/059238 patent/WO2009139497A1/en not_active Ceased
- 2009-05-13 PE PE2009000669A patent/PE20091924A1/es not_active Application Discontinuation
- 2009-05-13 CL CL2009001156A patent/CL2009001156A1/es unknown
- 2009-05-13 AR ARP090101720A patent/AR071774A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009139497A1 (en) | 2009-11-19 |
| AR071774A1 (es) | 2010-07-14 |
| RU2010150964A (ru) | 2012-06-20 |
| CN102149725A (zh) | 2011-08-10 |
| US20100112089A1 (en) | 2010-05-06 |
| PE20091924A1 (es) | 2010-01-04 |
| TW201000116A (en) | 2010-01-01 |
| CL2009001156A1 (es) | 2010-08-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2020013600A2 (es) | Tratamiento de la hidradenitis supurativa mediante el uso de inhibidores de jak | |
| CL2019001079A1 (es) | Métodos para usar indazol-3-carboxamidas y su uso como inhibidores de la vía de señalización de wnt/b-catenina. | |
| AR090349A1 (es) | Terapia de combinacion para trastornos proliferativos, kit y uso | |
| SV2015005115A (es) | Derivados de la pirazolopirrolidina y su uso en el tratamiento de enfermedades | |
| ECSP17013617A (es) | combinación farmacéutica que comprende 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y nsaid | |
| CO6650415A2 (es) | Nuevas formas de dosificacion de liberación modificada de un inhibidor de la xantina oxidorreductasa o de inhibidoes de xantina oxidasa | |
| CL2015002733A1 (es) | Composición farmacéutica de clorhidrato de s-cetamina. | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| CR11510A (es) | Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer | |
| MX2016015434A (es) | Combinaciones farmaceuticas para tratar cancer. | |
| CL2011002858A1 (es) | Uso de una composicion farmaceutica transmucosa oral que comprende dexmedetomidina y una sal farmaceuticamente aceptable y un excipiente farmaceuticamente aceptable para preparar un medicamento util para tratar o prevenir el dolor. | |
| BR112016012506A2 (pt) | Combinações farmacêuticas, seus usos, e uso de um portador de dados | |
| PE20142319A1 (es) | Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero | |
| BR112015009037A2 (pt) | composição farmacêutica para uso no tratamento de infarto do miocárdio e uso de um peptídeo de fragmento de hmgb1 | |
| MX2014002171A (es) | Tratamientos de combinacion para hepatitis c. | |
| UY30158A1 (es) | Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor | |
| AR097619A1 (es) | Uso de inhibidores de acetil-coa carboxilasa para tratar acné vulgaris | |
| UY31826A (es) | Compuesto peptídico y su uso | |
| MX2016015437A (es) | Combinacion que comprende un glucocorticoide y edo-s101. | |
| BR112014023423A2 (pt) | terapia de combinação | |
| PE20181332A1 (es) | Metodos de sedacion y formulacion parenteral para uso durante el tratamiento de cuidados criticos | |
| BR112015012497A2 (pt) | combinações farmacêuticas | |
| MX2013001279A (es) | Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral. | |
| CL2012003119A1 (es) | Composicion farmaceutica para inyeccion que compende una solucion acuosa de ibuprofeno y trometamol, en que la concentracion de ibuprofeno esta entre 2 y 6 mg/ml, la concentracion de trometamol esta entre 1.8 y 5.8 mg/ml, y el ph esta entre 7,0 y 9,5; y su uso para el tratamiento del dolor, la inflamacion o la fiebre. | |
| AR099299A1 (es) | Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 109 | Application deemed to be withdrawn |
Effective date: 20181026 |